143 related articles for article (PubMed ID: 12720138)
1. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia.
Merlini G; Baldini L; Broglia C; Comelli M; Goldaniga M; Palladini G; Deliliers GL; Gobbi PG
Semin Oncol; 2003 Apr; 30(2):211-5. PubMed ID: 12720138
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.
Baldini L; Goldaniga M; Guffanti A; Broglia C; Cortelazzo S; Rossi A; Morra E; Colombi M; Callea V; Pogliani E; Ilariucci F; Luminari S; Morel P; Merlini G; Gobbi P
J Clin Oncol; 2005 Jul; 23(21):4662-8. PubMed ID: 16034042
[TBL] [Abstract][Full Text] [Related]
3. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
[TBL] [Abstract][Full Text] [Related]
4. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.
Cesana C; Miqueleiz S; Bernuzzi P; Tresoldi E; Rossi V; D'avanzo G; Filippini D; Morra E
Semin Oncol; 2003 Apr; 30(2):231-5. PubMed ID: 12720142
[TBL] [Abstract][Full Text] [Related]
5. No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
Kastritis E; Kyrtsonis MC; Hatjiharissi E; Symeonidis A; Michalis E; Repoussis P; Tsatalas K; Michael M; Sioni A; Kartasis Z; Stefanoudaki E; Voulgarelis M; Delimpasi S; Gavriatopoulou M; Koulieris E; Gika D; Vervesou E; Konstantopoulos K; Kokkini G; Zomas A; Roussou P; Anagnostopoulos N; Economopoulos T; Terpos E; Zervas K; Dimopoulos MA
Am J Hematol; 2011 Jun; 86(6):479-83. PubMed ID: 21509798
[TBL] [Abstract][Full Text] [Related]
6. Asymptomatic Waldenstrom's macroglobulinemia.
Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).
Dhodapkar MV; Jacobson JL; Gertz MA; Crowley JJ; Barlogie B
Semin Oncol; 2003 Apr; 30(2):220-5. PubMed ID: 12720140
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic spectrum of Waldenström's macroglobulinemia: a single center experience.
Sajid R; Siddiqui SH; Shaikh U; Adil S
Indian J Pathol Microbiol; 2010; 53(3):490-3. PubMed ID: 20699509
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in Waldenstrom's macroglobulinemia: description of the complications during the evolution-preliminary results on 101 patients.
Stalnikiewicz L; Carrotte-Lefebvre I; Detourmignies L; Rose C; Cazin B; Leblond V; Morel P
Semin Oncol; 2003 Apr; 30(2):216-9. PubMed ID: 12720139
[TBL] [Abstract][Full Text] [Related]
10. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study.
Björkholm M; Johansson E; Papamichael D; Celsing F; Matthews J; Lister TA; Rohatiner AZ
Semin Oncol; 2003 Apr; 30(2):226-30. PubMed ID: 12720141
[TBL] [Abstract][Full Text] [Related]
11. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH).
Kastritis E; Kyrtsonis MC; Hadjiharissi E; Symeonidis A; Michalis E; Repoussis P; Tsatalas C; Michael M; Sioni A; Kartasis Z; Stefanoudaki E; Voulgarelis M; Delimpasi S; Gavriatopoulou M; Koulieris E; Gika D; Zomas A; Roussou P; Anagnostopoulos N; Economopoulos T; Terpos E; Zervas K; Dimopoulos MA;
Leuk Res; 2010 Oct; 34(10):1340-3. PubMed ID: 20447689
[TBL] [Abstract][Full Text] [Related]
12. Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase.
Kastritis E; Zervas K; Repoussis P; Michali E; Katodrytou E; Zomas A; Simeonidis A; Terpos E; Delimbassi S; Vassou A; Gika D; Dimopoulos MA;
Clin Lymphoma Myeloma; 2009 Mar; 9(1):50-2. PubMed ID: 19362972
[TBL] [Abstract][Full Text] [Related]
13. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
Weber DM; Dimopoulos MA; Delasalle K; Rankin K; Gavino M; Alexanian R
Semin Oncol; 2003 Apr; 30(2):243-7. PubMed ID: 12720145
[TBL] [Abstract][Full Text] [Related]
14. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.
Ghobrial IM; Fonseca R; Gertz MA; Plevak MF; Larson DR; Therneau TM; Wolf RC; Hoffmann RJ; Lust JA; Witzig TE; Lacy MQ; Dispenzieri A; Vincent Rajkumar S; Zeldenrust SR; Greipp PR; Kyle RA
Br J Haematol; 2006 Apr; 133(2):158-64. PubMed ID: 16611306
[TBL] [Abstract][Full Text] [Related]
15. Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathy.
Morra E; Cesana C; Klersy C; Varettoni M; Cavanna L; Canesi B; Tresoldi E; Barbarano L; Lazzarino M;
Semin Oncol; 2003 Apr; 30(2):172-7. PubMed ID: 12720131
[TBL] [Abstract][Full Text] [Related]
16. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
Dimopoulos MA; Hamilos G; Zervas K; Symeonidis A; Kouvatseas G; Roussou P; Gika D; Karmiris T; Bourantas K; Zomas A; Mitsouli C; Xilouri I; Vervessou E; Matsis K; Anagnostopoulos N; Economopoulos T;
Ann Oncol; 2003 Aug; 14(8):1299-305. PubMed ID: 12881396
[TBL] [Abstract][Full Text] [Related]
17. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
Gobbi PG; Baldini L; Broglia C; Goldaniga M; Comelli M; Morel P; Morra E; Cortelazzo S; Bettini R; Merlini G
Clin Cancer Res; 2005 Mar; 11(5):1786-90. PubMed ID: 15756000
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
Escudier B; Choueiri TK; Oudard S; Szczylik C; Négrier S; Ravaud A; Chevreau C; Venner P; Champagne P; Croteau D; Dupont E; Hariton C; Bukowski RM
J Urol; 2007 Nov; 178(5):1901-5. PubMed ID: 17868728
[TBL] [Abstract][Full Text] [Related]
19. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit.
Kyrtsonis MC; Vassilakopoulos TP; Angelopoulou MK; Siakantaris P; Kontopidou FN; Dimopoulou MN; Boussiotis V; Gribabis A; Konstantopoulos K; Vaiopoulos GA; Fessas P; Kittas C; Pangalis GA
Ann Hematol; 2001 Dec; 80(12):722-7. PubMed ID: 11797112
[TBL] [Abstract][Full Text] [Related]
20. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]